Update :


Our laboratories collaborate closely with lots of hospitals including Cancer Institute Ariake Hospital, and we analyze cell-free DNA (cfDNA) in order to (1) make it detectable before the "cancer" is discovered by images or tumor markers etc, (2) make it possible to diagnose the recurrence of cancer as soon as possible, (3) monitor the therapeutic effect more accurately. We are developing accurate and high sensitive diagnostic system using cfDNA.

“Liquid Biopsy” is a novel diagnosis which use patient’s blood, urine and so on. This technology is developing, and expected to be promising tool for cancer precision medicine.


  1. Investigation of clinical significance of liquid biopsy for malignant tumors.
  2. Clinical relevance of therapeutic monitering for patients with colorectal cancer using ctDNA.
  3. Exome analysis and liquid biopsy for DCIS of breast cancer.
  4. Clinical relevance of ctDNA as a predictive marker for patients with pancreatic cancer.
  5. Genome-wide association study for HR-positive breast cancer to develop appropriate hormonal therapy.
  6. Identification of markers for sensitivity to cytotoxic anticancer agents by whole exome analysis.
  7. Identification of genes associated with toxicity and efficacy of molecular targeted drugs, Regorafenib, Trastuzumab, and Nivolumab.




Hitoshi Zembutsu (Chief)
Project for Development of Liquid Biopsy Diagnosis,
Cancer Precision Medicine Center, Cancer Institute.
3-8-31, Ariake, Koto-ku, Tokyo, 135-8550, Japan
Tel: +81-3-3520-0111(5623)


Return to Top of Page